We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mast Cell Biomarker Predicts Severity of Dengue

By LabMedica International staff writers
Posted on 13 May 2013
A protein produced by mast cells in the immune system may predict which people infected with dengue virus will develop life-threatening complications.

Dengue virus (DENV) spread by mosquitoes, infects as many as 390 million people worldwide each year, and is a significant health issue in tropical areas of the world including parts of Latin America and Asia, and health professionals in Florida have reported cases in recent years. More...


Scientists at Duke University (Durham, NC, USA) working with their colleagues at Duke-National University of Singapore investigated the role of mast cells in attacking dengue virus in humans, and identified a biomarker derived from the mast cells, that appeared to predict the most severe cases of the disease in human patients.

Samples used for the investigation were derived from patients that ranged in age from 18 to 77 years, with a mean of 40 years; 42% of samples were obtained from females, and 58% from males. Dengue positive samples were determined based on physician diagnosis as well as molecular tests including reverse transcriptase polymerase chain reaction (RT-PCR) for viral ribonucleic acid (RNA).

The dengue fever (DF) and dengue hemorrhagic fever (DHF) patient sera used in this study were previously determined to be positive for serotypes 1, 2, or 3 by RT-PCR using the OneStep RT-PCR Kit (Qiagen; Valencia, CA, USA). Enzyme-linked immunosorbent assay (ELISA) kits for the human mast cell biomarker chymase, a serine protease, were obtained from Antibodies-Online (Atlanta, GA, USA).

Patients that were diagnosed with DF or DHF showed chymase levels in serum obtained during the acute phase of infection were significantly higher than levels in the serum of either healthy controls or individuals with fever that were DENV negative by RT-PCR. DF patients displayed an increase in serum chymase that was approximately 10 times higher than in healthy individuals or DENV-negative patients while, in DHF patients, chymase levels 30 times higher than healthy controls were detected.

Soman N. Abraham, PhD, a professor at Duke University and the senior author of the study, said,” In addition to revealing a potential new way to diagnose and treat dengue infections, these finding may have much broader applicability for other infectious diseases where vascular leakage is a major pathologic outcome.” The study was published on April 30, 2013, in the journal eLife.

Related Links:
Duke University
Duke-National University of Singapore
Antibodies-Online



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Test
Allplex HPV28 Detection
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.